Adela was founded by Daniel Diniz De Carvalho, Scott Bratman, Anne-Renee Hartman in 2020.

Who are Adela's investors?

Adela's investors include Decheng Capital, F-Prime Capital, OrbiMed, Deerfield Management Company, Menlo Ventures.

How much funding has Adela raised?

Adela has disclosed $113.5M raised across 6 rounds.

Where is Adela headquartered?

Adela is headquartered in Foster City, US.

Adela

Foster City, US · Founded 2020 · 71 employees on LinkedIn · 5 known investors

Find your way into Adela

1,417 people in our graph can introduce you to the Adela team.

Paths you didn't know you had: your email and LinkedIn already hold routes to the Adela team. We find them
2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Adela develops blood-based tests for cancer detection using epigenetics and liquid biopsy technology, aimed at helping patients and clinicians detect and act on cancer earlier. It serves the oncology and cancer care market.

Biotech Digital Health Healthtech Medical Devices

Founders & leadership

Adela was founded in 2020 by Daniel Diniz De Carvalho, Scott Bratman, and Anne-Renee Hartman.

Daniel Diniz De CarvalhoCo-founder

Scott BratmanCo-FounderExecutive Officer, Director at Adelabio

Anne-Renee Hartman Co-founder and Chief Medical OfficerAnne-Renee Hartman is founder of Adela, which develops blood-based cancer detection tests using epigenetics and liquid biopsy technology. She has 15+ years of experience in molecular diagnostics.

Alan WilliamsChief Operations OfficerExecutive Officer at Adelabio

Lisa Alderson Chief Executive Officer and President2023–2026Lisa Alderson is founder and executive officer of Adela, which develops blood-based cancer detection tests using epigenetic and liquid biopsy technology. She has built multiple companies in genomics, precision medicine, molecular diagnostics, and digital health, with experience in product launches, capital raising, and strategic partnerships in the healthcare sector.

Priscilla HuangSenior Vice President Finance2020–2025Executive Officer at Adelabio

Karla JarvisExecutiveExecutive Officer at Adelabio

Maneesh JainNamed on SEC filing

Anne-Renee Hartman FeldmanNamed on SEC filing

Board

Andrew ElBardissi Board MemberPartner at Deerfield Management Company

David Bonita Board directorGeneral Partner at OrbiMed

Paul BrownBoard director

Investors · 5

Decheng Capitallisted by Decheng CapitalMenlo Park

How we know: Decheng Capital's portfolio page · the VCSheet dataset · Not right? Tell us

F-Prime Capitallisted by F-Prime CapitalCambridge · $3M – $10M

How we know: F-Prime Capital's portfolio page · a partner's Signal profile · funding news · Not right? Tell us

OrbiMedlisted by OrbiMedNew York · $1M – $75M

How we know: OrbiMed's portfolio page · board seat on SEC Form D · funding news · the VCSheet dataset · Not right? Tell us

Deerfield Management CompanyreportedNew Yorkvia Andrew ElBardissi · board

How we know: board seat on SEC Form D · funding news · Not right? Tell us

Menlo VenturesreportedSan Francisco · $1M – $20M

How we know: funding news · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$113.5M disclosed across 6 rounds · 2021–2026

▶$5MraisedApr 2026 · 1 investors · Biotechnology

Rule 506(b)